Pfizer's (PFE) Pregabalin Missed Primary Endpoint in Phase 3
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced top-line results of a double-blind, placebo-controlled, Phase 3 study evaluating both the 165 mg dose ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
